N-Terminal amyloid-β antibodies
AssigneeNeuralab Limited
InventorDale B. Schenk
Life of this patent
Estimating the term…
Abstract
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred including N-terminal fragments of Aβ and antibodies binding to the same.
Claims7
A pharmaceutical composition comprising an antibody that specifically binds to an epitope within residues 1-7 of Aβ and a pharmaceutical carrier, wherein the isotype of said antibody is human IgG1.
A pharmaceutical composition comprising a chimeric or humanized antibody that specifically binds to an epitope within residues 1-7 of Aβ and a pharmaceutical carrier.
Dependencies are inferred from the claim text.